Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Katz, Steven C ^a   Burga, Rachel A ^a   Naheed, Seema ^a   Licata, Lauren A ^a   Thorn, Mitchell ^a   Osgood, Doreen ^a   Nguyen, Cang T ^a   Espat, N Joseph ^a   Fletcher, Jonathan A ^b   Junghans, Richard P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adoptive cell therapy; and Designer T cells; GIST; Immunotherapy

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; KIT ANTIBODY; PROTEIN ANTIBODY; RECEPTOR; RETROVIRUS VECTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; CELL ACTIVITY; CELL THERAPY; CHIMERA; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESIGNER T LYMPHOCYTE; GASTROINTESTINAL STROMAL TUMOR; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; T LYMPHOCYTE; TARGET CELL DESTRUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; DNA PRIMERS; GASTROINTESTINAL STROMAL TUMORS; MALE; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; T-LYMPHOCYTES;

EID: 84874008964     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-46     Document Type: Article

References (25)

1. Katz SC, DeMatteo RP. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 2008, 97:350-359. 10.1002/jso.20970, 18286477.
2. Parkkila S, Lasota J, Fletcher JA, Ou WB, Kivela AJ, Nuorva K, Parkkila AK, Ollikainen J, Sly WS, Waheed A. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 2010, 23:743-750. 10.1038/modpathol.2009.189, 2900582, 20081808.
3. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104. 10.1016/S0140-6736(09)60500-6, 2915459, 19303137.
4. Janicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K, Porter AG. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells. Oncogene 2001, 20:5043-5053. 10.1038/sj.onc.1204659, 11526489.
5. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321. 10.1126/science.3489291, 3489291.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308. 10.1038/nrc2355, 2553205, 18354418.
7. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res 2008, 14:8112-8122. 10.1158/1078-0432.CCR-07-4910, 2659496, 19088026.
8. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45. 10.1038/nrc971, 12509765.
9. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002, 2:512-519. 10.1038/nri841, 12094225.
10. Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A, Wright G, Perro M, Little AM, Pospori C. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther 2007, 15:1744-1750. 10.1038/sj.mt.6300216, 17637721.
11. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849, 3387277, 21830940.
12. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924. 10.1200/JCO.2010.32.2537, 3068063, 21282551.
13. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20:5054-5058. 10.1038/sj.onc.1204704, 11526490.
14. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161. 10.1158/0008-5472.CAN-06-0165, 16982758.
15. Muhlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009, 69:6941-6950. 10.1158/0008-5472.CAN-08-4004, 2905726, 19706776.
16. Takagi S, Saito Y, Hijikata A, Tanaka S, Watanabe T, Hasegawa T, Mochizuki S, Kunisawa J, Kiyono H, Koseki H. Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation. Blood 2012, 119:2768-2777. 10.1182/blood-2011-05-353201, 22279057.
17. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296. 10.1084/jem.188.2.287, 2212461, 9670041.
18. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100. 10.1038/nm.2438, 3278279, 21873989.
19. Ley K, Bullard DC, Arbones ML, Bosse R, Vestweber D, Tedder TF, Beaudet AL. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J Exp Med 1995, 181:669-675. 10.1084/jem.181.2.669, 2191869, 7530761.
20. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem 1998, 273:7118-7122. 10.1074/jbc.273.12.7118, 9507024.
21. Pouw N, Treffers-Westerlaken E, Kraan J, Wittink F, ten Hagen T, Verweij J, Debets R. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother 2010, 59:921-931. 10.1007/s00262-010-0818-0, 20101507.
22. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998, 188:619-626. 10.1084/jem.188.4.619, 2213361, 9705944.
23. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010, 16:2769-2780. 10.1158/1078-0432.CCR-10-0043, 20460472.
24. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645. 10.1016/j.immuni.2009.04.010, 19464986.
25. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997, 90:1345-1364.